250 related articles for article (PubMed ID: 27764023)
1. Sustained drug delivery for glaucoma: current data and future trends.
Aref AA
Curr Opin Ophthalmol; 2017 Mar; 28(2):169-174. PubMed ID: 27764023
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
Stewart WC; Konstas AG; Nelson LA; Kruft B
Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
[TBL] [Abstract][Full Text] [Related]
3. Sustained drug delivery in glaucoma.
Knight OJ; Lawrence SD
Curr Opin Ophthalmol; 2014 Mar; 25(2):112-7. PubMed ID: 24463419
[TBL] [Abstract][Full Text] [Related]
4. Additivity of bimatoprost or travoprost to latanoprost in glaucomatous monkey eyes.
Gagliuso DJ; Wang RF; Mittag TW; Podos SM
Arch Ophthalmol; 2004 Sep; 122(9):1342-7. PubMed ID: 15364714
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications.
Noecker RJ; Walt JG
Am J Ophthalmol; 2006 Jan; 141(1 Suppl):S15-21. PubMed ID: 16389056
[TBL] [Abstract][Full Text] [Related]
6. Latanoprost : an update of its use in glaucoma and ocular hypertension.
Perry CM; McGavin JK; Culy CR; Ibbotson T
Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
[TBL] [Abstract][Full Text] [Related]
7. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.
Easthope SE; Perry CM
Drugs Aging; 2002; 19(3):231-48. PubMed ID: 12027782
[TBL] [Abstract][Full Text] [Related]
8. Patient Acceptance of Sustained Glaucoma Treatment Strategies.
Varadaraj V; Kahook MY; Ramulu PY; Pitha IF
J Glaucoma; 2018 Apr; 27(4):328-335. PubMed ID: 29462013
[TBL] [Abstract][Full Text] [Related]
9. Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension.
Cantor LB; WuDunn D; Cortes A; Hoop J; Knotts S
Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S12-8. PubMed ID: 15016557
[TBL] [Abstract][Full Text] [Related]
10. A model-based dose-response meta-analysis of ocular hypotensive agents as a drug development tool to evaluate new therapies in glaucoma.
Raber S; Mandema JW; Li H; Nickens DJ
J Ocul Pharmacol Ther; 2015 May; 31(4):189-97. PubMed ID: 25714918
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma.
Christiansen GA; Nau CB; McLaren JW; Johnson DH
Ophthalmology; 2004 Sep; 111(9):1658-62. PubMed ID: 15350319
[TBL] [Abstract][Full Text] [Related]
12. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
[TBL] [Abstract][Full Text] [Related]
13. Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials.
Li N; Chen XM; Zhou Y; Wei ML; Yao X
Clin Exp Ophthalmol; 2006 Nov; 34(8):755-64. PubMed ID: 17073898
[TBL] [Abstract][Full Text] [Related]
14. Sustained release glaucoma therapies: Novel modalities for overcoming key treatment barriers associated with topical medications.
Belamkar A; Harris A; Zukerman R; Siesky B; Oddone F; Verticchio Vercellin A; Ciulla TA
Ann Med; 2022 Dec; 54(1):343-358. PubMed ID: 35076329
[TBL] [Abstract][Full Text] [Related]
15. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy.
Denis P; Lafuma A; Khoshnood B; Mimaud V; Berdeaux G
Curr Med Res Opin; 2007 Mar; 23(3):601-8. PubMed ID: 17355741
[TBL] [Abstract][Full Text] [Related]
16. Extraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma.
Kompella UB; Hartman RR; Patil MA
Prog Retin Eye Res; 2021 May; 82():100901. PubMed ID: 32891866
[TBL] [Abstract][Full Text] [Related]
17. [Bimatoprost therapy in glaucoma].
Călugăru D; Călugăru M
Oftalmologia; 2009; 53(3):34-45. PubMed ID: 19899545
[TBL] [Abstract][Full Text] [Related]
18. Estimated comparative costs of achieving a 20% reduction in intraocular pressure with bimatoprost or latanoprost in patients with glaucoma or ocular hypertension.
Fiscella R; Walt J
Drugs Aging; 2006; 23(1):39-47. PubMed ID: 16492068
[TBL] [Abstract][Full Text] [Related]
19. Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study.
Lopes JF; Hubatsch DA; Amaris P
BMC Ophthalmol; 2015 Nov; 15():166. PubMed ID: 26563363
[TBL] [Abstract][Full Text] [Related]
20. The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma.
Yildirim N; Sahin A; Gultekin S
J Glaucoma; 2008; 17(1):36-9. PubMed ID: 18303382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
